Zografos L, Wolin D, Andrews E, Calingaert B, Balabanova Y, Horvat-Brocker A, Tarenz C, Suzart-Woischnik K. Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. Expert Opin Drug Saf. 2022 Mar;21(3):435-46. doi: 10.1080/14740338.2022.1998451
Patterson BJ, Buck PO, Curran D, Van Oorschot D, Carrico J, Herring WL, Zhang Y, Stoddard JJ. Estimated public health impact of the recombinant zoster vaccine. Mayo Clin Proc Innov Qual Outcomes. 2021 May 26;5(3):596-604. doi: 10.1016/j.mayocpiqo.2021.03.006
Margulis AV, Houben E, Hallas J, Overbeek JA, Pottegard A, Torp-Pedersen T, Perez-Gutthann S, Arana A. Ophthalmic nepafenac use in the Netherlands and Denmark. Acta Ophthalmol. 2017 Aug;95(5):509-17. doi: 10.1111/aos.13468
King RM, Vidrine DJ, Danysh HE, Fletcher FE, McCurdy S, Arduino RC, Gritz ER. Factors associated with nonadherence to antiretroviral therapy in HIV-positive smokers. AIDS Patient Care STDS. 2012 Aug;26(8):479-85. doi: 10.1089/apc.2012.0070
Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart RC. Comparative risks of non-prescription analgesics: a structured topic review and research priorities. Expert Opin Drug Saf. 2012 Jan 1;11(1):33-44.
Bray JW, Davis KL, Graver L, Schroeder D, Buck JA, Dilonardo J, Vandivort R. Mental health and substance abuse treatment utilization among individuals served by multiple public agencies in 3 states. J Behav Health Serv Res. 2005 Jan 1;32(3):282-93.